Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 12/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16540967 | 0.81 | CYP11B1 (0.43) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL22145957 | 0.81 | CYP11B1 (0.43) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL14809711 | 0.81 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL1322438 | 0.81 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL12832005 | 0.79 | COMT (0.51) | CYP11B1CYP11B2GAA | |
| SCHEMBL24242352 | 0.78 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL18135592 | 0.78 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL25527215 | 0.78 | CYP11B1 (0.42) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL22146339 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL16160311 | 0.78 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012078994-A1 | IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP11B1 1168/4885CYP11B2 1579/4885CYP19A1 425/4885 |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | CYP11B1 3773/4885CYP11B2 3606/4885CYP19A1 3945/4885 |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | CYP11B1 3753/4885CYP11B2 4388/4885CYP19A1 3735/4885 |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | BMI1, BAZ2A, BRPF3 | CYP11B1 4223/4885CYP11B2 4662/4885CYP19A1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.